Gilead Sciences' TROP2-directed drug Trodelvy has missed the target in another clinical trial, this time in urothelial carcinoma, the most common form of bladder cancer. The results of the TROPiCS ...

The results of Gilead's much-anticipated TROPiCS-02 study of Trodelvy are in, and while the company says top-line data are positive, its guarded stance has rung some alarm bells.

Last month, the Dutch Ministry of Health, Welfare and Sport (VWS) announced that it will not include the cancer drug Trodelvy (sacituzumab govitecan-hziy) in the country’s standard package of ...

Entered into an additional clinical study collaboration and supply agreement with Gilead to evaluate IDE397, IDEAYA's MAT2A inhibitor, in combination with Trodelvy, Gilead's Trop-2 directed ADC ...

Gilead’s Trodelvy is currently approved for second-line or later metastatic triple-negative breast cancer (TNBC) patients in more than 50 countries and for certain patients with pre-treated HR+ ...

What else you have?'" After two failed therapies, Keenan qualified for a drug called Trodelvy. It's what doctors call an antibody-drug conjugate. "And what that means is that we take an antibody ...

(Gilead) to evaluate the efficacy and safety of IDE397, its investigational, potential first-in-class, small molecule MAT2A inhibitor, in combination with Gilead's Trodelvy® (sacituzumab ...